Brainstorm Cell Therapeutics Inc. (BCLI) financial statements (2021 and earlier)

Company profile

Business Address 1325 AVENUE OF AMERICAS
NEW YORK, NY 10019
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments42291614123
Cash and cash equivalents38251212121
Short-term investments4442002
Receivables0100222
Prepaid expense    011
Other undisclosed current assets1000000
Total current assets:43301715356
Noncurrent Assets
Other noncurrent assets8233333
Total noncurrent assets:8233333
TOTAL ASSETS:51331918789
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7476161110
Accounts payable53551599
Accrued liabilities1121121
Debt  111  
Other undisclosed current liabilities5211111
Total current liabilities:11698181211
Noncurrent Liabilities
Long-term debt and lease obligation501113 
Operating lease, liability501113 
Other undisclosed noncurrent liabilities (0)    3
Total noncurrent liabilities:5011133
Total liabilities:16799191513
Commitments and contingencies1      
Stockholders' equity
Stockholders' equity attributable to parent3526109(12)(7)(5)
Common stock0000000
Treasury stock, value(0)      
Additional paid in capital18516314313410510399
Accumulated deficit(149)(137)(133)(125)(117)(110)(104)
Other undisclosed stockholders' equity(1)      
Total stockholders' equity:3526109(12)(7)(5)
TOTAL LIABILITIES AND EQUITY:51331918789

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(11)(4)(7)(8)(8)(6)(5)
Operating loss:(11)(4)(7)(8)(8)(6)(5)
Other undisclosed loss from continuing operations before equity method investments, income taxes(0)   (0)  
Loss before gain (loss) on sale of properties:(12)(4)(7)(8)(8)(6)(5)
Other undisclosed net income (loss)(0)(0)000(0) 
Net loss:(12)(4)(7)(8)(8)(6)(5)
Other undisclosed net loss attributable to parent      (0)
Net loss available to common stockholders, diluted:(12)(4)(7)(8)(8)(6)(5)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(12)(4)(7)(8)(8)(6)(5)
Comprehensive loss, net of tax, attributable to parent:(12)(4)(7)(8)(8)(6)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: